A global Phase III clinical trial evaluating a new first-line treatment strategy for advanced breast cancer has missed its primary endpoint. AstraZeneca announced on 11 September 2026 that SERENA-4, which tested Etcamah — the brand name for camizestrant — plus palbociclib, did not show a statistically significant improvement in progression-free survival compared with anastrozole plus palbociclib. The company said a numerical improvement was observed and that detailed results will be presented later.

What “missed the primary endpoint” means

The primary endpoint was investigator-assessed progression-free survival, or PFS: how long patients remain alive without their disease progressing under RECIST criteria. The predefined statistical threshold required to show superiority was not met, according to AstraZeneca. A numerical difference that is not statistically significant does not establish that the investigational combination is superior on the primary endpoint, and it does not mean the treatment has been shown to “work” on that measure.

The SERENA-4 trial

SERENA-4 (NCT04711252) is a Phase III, randomised, double-blind, global trial. AstraZeneca said it enrolled 1,371 adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who had not received prior systemic treatment for advanced disease. The population included both de novo Stage IV disease and recurrence after earlier-stage breast cancer. The experimental regimen was camizestrant plus palbociclib versus anastrozole plus palbociclib. ClinicalTrials.gov still lists the study as not having posted results; a company press release is not a peer-reviewed paper.

What camizestrant is

Camizestrant is an oral selective estrogen receptor degrader, or SERD, designed to degrade the estrogen receptor and block hormone signalling that can drive some breast tumours. Etcamah is AstraZeneca’s commercial name. It is not a treatment for every form of breast cancer. Use depends on tumour biology, receptor status, identified mutations and line of therapy.

Breast cancer is not a single disease. ER-positive means tumour cells express estrogen receptors; HER2-negative means the tumour does not show the HER2 overexpression or amplification that defines other subtypes. In the notes to its announcement, AstraZeneca cites NCI SEER data that about 70% of breast tumours are HR-positive and HER2-negative. That figure is reported as the company’s cited statistic, not as an independent estimate by this newsroom.

Safety and data still to come

AstraZeneca said the safety profile of Etcamah plus palbociclib in SERENA-4 was consistent with the known safety profiles of the individual medicines and that no new safety signals were identified in the trial, according to the company. That wording does not mean the regimen is free of adverse effects or is “completely safe”.

At the time of the announcement, the company had not published complete PFS values, confidence intervals, subgroup analyses or the remaining detailed efficacy findings. Further interpretation should wait for the full dataset. There is not yet an independent peer-reviewed publication of the SERENA-4 results.

SERENA-4 is not SERENA-6

The missed primary endpoint in SERENA-4 does not mean camizestrant has no established clinical use. AstraZeneca says Etcamah plus a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) is already approved in the United States, the European Union, Japan and several other countries for certain adults with HR-positive or ER-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected or emerges during first-line endocrine-based therapy. Those approvals rest on SERENA-6, a separate Phase III trial in a biomarker-selected population, not on SERENA-4.

ESR1 is the gene that encodes the estrogen receptor. In some breast tumours, ESR1 mutations can arise during endocrine treatment and contribute to hormone-therapy resistance. The two trials should not be conflated: SERENA-4 tested replacing anastrozole with camizestrant from the start of first-line therapy in a broader population not selected for ESR1 mutation; SERENA-6 enrolled patients in whom an ESR1 mutation emerged during first-line therapy.

A wider programme, and why negative trials matter

AstraZeneca is still studying camizestrant in earlier-stage breast cancer, including the Phase III CAMBRIA-1 and CAMBRIA-2 trials. The company says its oral SERD clinical programme includes about 10,000 patients. The SERENA-4 result does not predict the outcome of CAMBRIA-1 or CAMBRIA-2; those are different studies.

A Phase III trial that misses its primary endpoint is still important scientific information. It can show that a strategy that looked promising in earlier phases did not deliver a statistically confirmed benefit in a broad first-line population, or that patient selection may need to remain narrower. SERENA-4 does not prove that the medicine “failed completely”; it shows that superiority on PFS was not statistically confirmed in this comparison. This article reports a clinical trial. It is not medical advice. People receiving cancer treatment should not start, stop or change therapy on the basis of this announcement; those decisions belong with the clinical team that knows the patient’s diagnosis and history.

Source consulted: Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer (AstraZeneca, 11 September 2026). Protocol and design: SERENA-4 — NCT04711252 (ClinicalTrials.gov).